Fourpath Capital Management LLC Purchases New Position in Insulet Corporation $PODD

Fourpath Capital Management LLC bought a new position in shares of Insulet Corporation (NASDAQ:PODD) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 717 shares of the medical instruments supplier’s stock, valued at approximately $225,000.

Several other hedge funds have also added to or reduced their stakes in the business. Nissay Asset Management Corp Japan ADV boosted its position in Insulet by 0.6% during the 1st quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock worth $2,222,000 after buying an additional 48 shares during the period. Mather Group LLC. boosted its position in Insulet by 4.4% during the 2nd quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock worth $360,000 after buying an additional 48 shares during the period. Brooklyn Investment Group boosted its position in Insulet by 7.0% during the 1st quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock worth $209,000 after buying an additional 52 shares during the period. Cooper Financial Group boosted its position in Insulet by 5.7% during the 1st quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier’s stock worth $283,000 after buying an additional 58 shares during the period. Finally, HighTower Advisors LLC boosted its position in Insulet by 2.1% during the 1st quarter. HighTower Advisors LLC now owns 2,882 shares of the medical instruments supplier’s stock worth $757,000 after buying an additional 60 shares during the period.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Wall Street Zen upgraded shares of Insulet from a “hold” rating to a “buy” rating in a research report on Saturday, August 9th. Piper Sandler boosted their price target on shares of Insulet from $320.00 to $360.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Citigroup restated a “buy” rating on shares of Insulet in a research report on Tuesday, July 8th. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a research report on Wednesday. Finally, Barclays boosted their price target on shares of Insulet from $266.00 to $300.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 21st. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Insulet has an average rating of “Moderate Buy” and an average target price of $347.67.

Insulet Stock Down 1.8%

Insulet stock opened at $314.52 on Friday. The company has a quick ratio of 1.81, a current ratio of 2.26 and a debt-to-equity ratio of 0.64. Insulet Corporation has a 12-month low of $226.50 and a 12-month high of $353.50. The firm’s fifty day moving average is $323.75 and its 200 day moving average is $300.12. The company has a market capitalization of $22.14 billion, a PE ratio of 95.60, a PEG ratio of 2.66 and a beta of 1.40.

Insulet (NASDAQ:PODD) last released its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The company had revenue of $649.10 million for the quarter, compared to the consensus estimate of $612.31 million. During the same quarter in the previous year, the company earned $0.55 EPS. Insulet’s quarterly revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, sell-side analysts predict that Insulet Corporation will post 3.92 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $348.81, for a total transaction of $278,001.57. Following the transaction, the senior vice president owned 3,890 shares in the company, valued at $1,356,870.90. The trade was a 17.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Prem Singh sold 687 shares of the business’s stock in a transaction on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. This trade represents a 16.58% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.